Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States

Conclusions There remains a knowledge gap with regard to biosimilars, and lack of consensus on how the naming convention is and should be utilized in clinical practice. The data also suggest that effective biosimilar education could aid in promoting familiarity with the naming convention among health care pro viders.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research